Sign Out
Asthma: Salmeterol xinafoate and fluticasone propionate inhalation powder is indicated in the regular treatment of asthma where use of a combination product (long-acting β2 agonist and inhaled corticosteroid) is appropriate: patients not adequately controlled with inhaled corticosteroids and 'as needed' inhaled short-acting β2 agonist or patients already adequately controlled on both inhaled corticosteroid and long-acting β2 agonist.
Note: Salmeterol and fluticasone propionate 50 microgram/100 microgram strength is not appropriate in adults and children with severe asthma.
Chronic Obstructive Pulmonary Disease (COPD): Salmeterol and fluticasone propionate dry powder inhaler (50 micrograms salmeterol and 250 microgram fluticasone propionate) is indicated for the symptomatic treatment of patients with COPD, with a FEV1 <60% predicted normal (pre-bronchodilator) and a history of repeated exacerbations, who have significant symptoms despite regular bronchodilator therapy.
Continue with Google